# Semaglutide curbs renal vascular resistance and fibrosis in phase 2 trial

- Published: 2026-11-10 09:59 UTC
- Section: Life & Health › Medicine
- Tags: semaglutide clinical trial, chronic kidney disease semaglutide, REMODEL trial results, GLP-1 receptor agonist kidney, renal vascular resistance, renal biopsy spatial transcriptomics
- URL: https://realtech.media/news/rt-b9ad5e88ee17a1d18179bfb1_semaglutide_curbs_renal/

**A 52-week clinical study revealed that once-weekly semaglutide protects renal microvasculature and stabilizes tissue structure in chronic kidney disease.**

![Semaglutide curbs renal vascular resistance and fibrosis in phase 2 trial](https://realtech.media/media/2026/11/cab1bf019bf1e476.png)
*nature.com*

Researchers have identified specific cellular and vascular mechanisms through which the GLP-1 receptor agonist semaglutide protects kidney function in adults with type 2 diabetes and chronic kidney disease, according to nature.com [1]. The randomized REMODEL trial enrolled 106 participants across 28 sites in eight countries between April 2021 and October 2023 [1]. Patients received either 1 mg of subcutaneous semaglutide or a placebo once weekly for 52 weeks to assess renal physiological and molecular responses [1].

## Imaging and hemodynamic outcomes

The trial's coprimary endpoints evaluated kidney oxygenation via R2* mapping, global tissue perfusion, and tissue inflammation using MRI T1 mapping [1]. Over the 52-week treatment period, these coprimary measures did not show statistically significant differences between the semaglutide and placebo cohorts [1]. However, secondary hemodynamic outcomes demonstrated a statistically significant decrease in the renal artery resistive index among patients receiving semaglutide [1]. Furthermore, apparent diffusion coefficient values stabilized, indicating prevention of kidney fibrosis progression [1].

## Transcriptomic and cellular profiling

To capture structural changes, investigators analyzed paired kidney biopsies collected before and after treatment from 33 participants [1]. Single-nucleus RNA sequencing on 22 samples and spatial transcriptomics on 13 samples indicated pronounced regulatory changes in glomerular endothelial cells [1]. Spatial analyses confirmed a reduction in the density of inflammatory immune cells in close proximity to these endothelial cells [1]. The authors concluded that semaglutide's therapeutic effects involve lowering vascular resistance, preserving tissue integrity, and maintaining microvascular health [1].

## Sources

1. [nature.com](https://www.nature.com/articles/s41591-026-04674-2)
2. [Science News](https://www.sciencenews.org/article/semaglutide-chronic-kidney-disease)

---

Source: RealTech, realtech.media — https://realtech.media/news/rt-b9ad5e88ee17a1d18179bfb1_semaglutide_curbs_renal/